Chandan Healthcare Limited · NSE:CHANDAN
Chandan Healthcare — H1 FY26 Earnings Presentation
39 slides from Chandan Healthcare's earnings presentation, Nov 17, 2025
Slide 1: Chandan Healthcare Limited - Investor Presentation Cover Letter
CHANDAN HEALTHCARE LIMITED Reg. Off. Add: Biotech Park, Sector-G, Jankipuram, Kursi Road, Lucknow-226021 CIN: L85110UP2003PLC193493 TELNO.: -8069366666 Email: secretarial@chandan.co.in www.chandandiagnostic.com Date: November 17, 2025 To, THE MANAGER, Listing and Compliance Department NSE Emerge NSE
Slide 2: Chandan Healthcare Limited Investor Presentation H1 FY26
Chandan Healthcare Limited Investor Presentation H1 FY26
Slide 3: Disclaimer
Disclaimer This presentation and the accompanying slides (the Presentation), which have been prepared by Chandan Healthcare (Chandan, The Company) solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not
Slide 4: Management Comments On H1 FY26 Financial Performance
Management Comments On H1 FY26 Financial Performance Amar Singh Promoter, Chairman and Managing Director H1 FY26 marked a period of robust growth, with revenue up 23.38% to ₹ 137 Cr and profitability remaining strong. The performance was supported by consistent volume growth, better business mix, an
Slide 5: H1 FY26 Consolidated Key Financials Highlights
H1 FY26 Consolidated Key Financials Highlights Total Income EBITDA PAT EBITDA % PAT % 29.98 137.49 21.81% 111.44 18.69% 20.83 15.60 10.64 11.35% 9.55% H1 FY25 H1 FY26 H1 FY25 H1 FY26 H1 FY25 H1 FY26 All Amount In ₹ Cr & Margins In % Investor Presentation 4
Slide 6: H1 FY26 Consolidated Profit & Loss Statement
H1 FY26 Consolidated Profit & Loss Statement In ₹ Cr Particulars H1 FY25 H1 FY26 Y-O-Y Operating Income 110.46 135.80 Other Income 0.98 1.69 Total Income 111.44 137.49 23.38% Raw Material Expenses 51.66 68.89 Employee Benefit Expenses 18.65 19.62 Other expenses 20.31 19.00 Total Expenditure 90.62 10
Slide 7: H1 FY26 Operational Highlights
H1 FY26 Operational Highlights New Diagnostic Centre, Ashiyana (Lucknow) Launch of Chandan Medical Centres • Comprehensive pathology, radiology, imaging, and preventive services. • Affordable diagnostics, consultations, • Supports expansion strategy through and medicines for semi-urban and IPO proce
Slide 8: Company Overview
Company Overview Redefining Diagnostics & Pharmacy in North India Investor Presentation 7
Slide 9: Chandan at a Glance
Chandan at a Glance Chandan Healthcare Limited is one of the leading North India-based providers of diagnostic and pharmacy services, and a key entity within the Chandan Group. The Company offers a comprehensive suite of NABL/NABH-accredited pathology and radiology solutions across Uttar Pradesh and
Slide 10: Key Facts & Figures
Key Facts & Figures 20+ 18.21 Lakh Years Of Industry Experience Total Patient Count (FY25) Decision making icon 1300+ 53.98 Lakh + Team Size Total Test Conducted(FY25) NABH MIS 360 Collection Centres Accreditation For 5 centres 40 NABL Accreditation Diagnostic Centres For 10 Labs Presence 35 Cities
Slide 11: Key Events & Achievements
Key Events & Achievements 2025 2018 Listed in Stock Exchange Won Most Innovative 2025 Crossed turnover of Healthcare Service Provider ₹ 200 Cr 2003 Started its first 2022 diagnostic centre in Crossed turnover of 20 ₹ 100 Cr Indra Nagar Lucknow 23 2003 2013 2019 2024 Incorporation of our Started its
Slide 12: Chandan Group Overview
Chandan Group Overview Chandan Group of Companies HOSPITALS DIAGNOSTICS PHARMACY PHAMACEUTICALS Chandan Healthcare Limited Chandan Hospital Chandan Pharmacy Limited Cendana Pharmaceuticals Chandan Super Limited Private Limited Speciality Limited Presence Uttar Pradesh – 19 Cities Presence Uttarakhan
Slide 13: Board Of Directors
Board Of Directors Amar Singh Asmita Singh Vinay Lamba Promoter, Chairman and Managing Director Promoter and Managing Director Non-Executive Director MBBS with 20+ years of experience in the BBA and MBA with 20+ years of marketing Marine Engineer with 10+ years of experience in healthcare industry e
Slide 14: Business Overview
Business Overview Multi-Segment Model Driving Growth Across B2C, B2B & B2G Investor Presentation 13
Slide 15: Chandan's Core Business Verticals
Chandan’s Core Business Verticals Pathology Radiology Pharmacy FY25 Revenue FY25 Revenue FY25 Revenue ₹96.50 Cr ₹ 27.80 Cr ₹ 105.80 Cr (41.94%) (12.08%) (45.98%) Investor Presentation 14
Slide 16: Balanced Business Model Across Retail, Government & Institutions
Balanced Business Model Across Retail, Government & Institutions Diversified revenue streams ensure stability, scalability, and reduced risk. B2C (Retail Diagnostics) B2B (Institutional Clients) B2G (Government PPPs) • Walk-in services across 35+ • 230+ private hospitals & clinics as • Public-Privat
Slide 17: Top Performing Centres Across Categories
Top Performing Centres Across Categories 13 Large Centres 6 Medium Centres 21 Small Centres Equipped with MRI & advanced Provide CT facilities, but no Basic healthcare & imaging for comprehensive MRI; focus on essential diagnostics without MRI/CT; diagnostics imaging services cater to Tier-2/3 regio
Slide 18: Expansive Regional Footprint Across North & Central India
Expansive Regional Footprint Across North & Central India State-wise Revenue In % The complete network comprises large, medium, and small centers and 360 sample collection centers. 29% Uttar Pradesh ₹ 230.10 Cr Uttarakhand 71% Glimpse Of Chandan’s Diagnostic Centres Large Medium Small Investor Prese
Slide 19: Enhancing Diagnostic Capabilities Through Capex
Enhancing Diagnostic Capabilities Through Capex Jankipuram, Lucknow Ashiyana, Lucknow Ayodhya, Uttar Pradesh Total capex investment: ₹24.68 Cr Total capex investment: ₹7.10 Cr Total capex investment: ₹7.10 Cr Purpose: Establishment of advanced Purpose: Diagnostic infrastructure Purpose: Setup of mul
Slide 20: Certified By India's Top Accrediting Bodies
Certified By India’s Top Accrediting Bodies Recognized For Quality Care With 5 NABH-Accredited Centres And 10 NABL-Crtified Labs. NABH Indira Nagar NABH MKP Chowk NABH Prayagraj NABL Indira Nagar NABL MKP Chowk UK NABL Karachi Khana Investor Presentation 19
Slide 21: Technology-Driven Healthcare at Chandan
Technology-Driven Healthcare at Chandan • 90+ Specialties 100K+ Downloads Available On • 24x7 Access On Play store IOS • One App for All Healthcare Needs Chandan 24x7 Digital-first platform strengthening customer loyalty & operational efficiency Unified Platform Diagnostics, Pharmacy & Doctor Consul
Slide 22: Affordable Healthcare, Strengthened Loyalty
Affordable Healthcare, Strengthened Loyalty Chandan Family Loyalty Card An integrated healthcare membership programme offering patients savings, convenience & holistic family coverage. Key Privileges Strategic Impact for Chandan • Family-wide coverage with one card • Boosts customer loyalty & repeat
Slide 23: Pharmacy Segment – Strong Complement To Diagnostics
Pharmacy Segment – Strong Complement To Diagnostics Pharmacy contributes ₹ 105.8 Cr (~46% of Chandan’s FY25 revenue), with a strong retail-driven model, steady institutional demand, and synergy with diagnostic services. Service Strengths In % In % Consumer Category Wise Sales Product Category Wise S
Slide 24: Key Strengths Driving Sustainable Growth
Key Strengths Driving Sustainable Growth Integrated Diagnostic Platform Digital Ecosystem with Strong Adoption Offers 1,118+ pathology and radiology tests under 100K+ downloads of Chandan 24x7 App NABL/NABH-accredited infrastructure offering e-pharmacy, doctor consultations, test bookings, and digit
Slide 25: Expanding Footprint Across India
Expanding Footprint Across India Network Expansion Plan Expansion Highlights • Targeting a network of 100 labs across 17 states over • New States: Entry into Delhi, Madhya Pradesh & the next 3 years Chhattisgarh • Expanding presence through 1,000 franchises in the • Strengthening Presence: Deepening
Slide 26: Future Roadmap: Chandan Healthcare
Future Roadmap: Chandan Healthcare Maintaining Capital Efficiency: Unlocking Future Value: Fund growth primarily through Explore value unlocking internal accruals; raise capital via pharmacy selectively. restructuring once diagnostics achieve scale. Leveraging Technology for Differentiation: Deploy
Slide 27: Industry Overview
Industry Overview Healthcare Demand Rising Across India’s Metro & Tier-2/3 Cities Investor Presentation 26
Slide 28: Indian Healthcare Industry Overview
Indian Healthcare Industry Overview The Indian Healthcare Sector Is Entering Its Golden Decade. The Indian healthcare market is Indian Healthcare Industry Size in projected to grow from approximately (US$ Billion) US$ 367 billion by 2023 to 700 US$ 638 billion by 2025, representing a 638 Public heal
Slide 29: Indian Diagnostics Sector Overview
Indian Diagnostics Sector Overview Market Size & Growth • Diagnostics industry expected to grow from US$13 Billion (FY23) to US$25 Billion (FY28) at a 14% CAGR. Indian Diagnostic Market (US$ Billion) • Growth driven by rising chronic diseases, ageing population, demand for preventive tests, and wide
Slide 30: Financial Overview
Financial Overview Consistent Growth Backed by Scale, Efficiency & Expansion Investor Presentation 29
Slide 31: Financial Highlights
Financial Highlights Year On Year Revenue Growth Fixed Asset Turnover Interest Coverage Return on Equity 30.57% 2.86 Times 7.95 Times 27.08% Year on Year Profit Return on capital Growth Employed Debt to Equity Book Value 36.17% 29.34% 0.39 Times ₹ 50.14 Investor Presentation 30
Slide 32: Key Financial Highlights
Key Financial Highlights (All Amount In ₹ Cr & Margins In %) Total Income EBITDA EBITDA Margin PAT PAT Margin 50 27.00% 25 27.00% 232.17 43.38 22.17 45 22.00% 22.00% 40 18.69% 20 177.81 35 15.53% 17.00% 17.00% 16.27 27.62 30 137.03 12.00% 15 12.00% 25 6.95% 7.00% 9.22% 9.63% 7.00% 20 10 15 2.00% 2.0
Slide 33: Consolidated Profit & Loss Statement
Consolidated Profit & Loss Statement (In ₹ Cr) Particulars FY23 FY24 FY25 Revenues 136.89 176.59 230.12 Other Income 0.14 1.22 2.05 Total Income 137.03 177.81 232.17 Raw Material Expenses 64.71 80.85 107.62 Employee Costs 25.49 35.42 38.86 Other Expenses 37.30 33.92 42.31 Total Expenditure 127.51 15
Slide 34: Consolidated Balance Sheet
Consolidated Balance Sheet (In ₹ Cr) Equities & Liabilities FY23 FY24 FY25 Assets FY23 FY24 FY25 Equity 20.00 20.00 24.45 Non-Current Assets Reserves And Surplus 2.76 21.16 98.15 Fixed assets 32.56 48.49 80.45 Total Equity 22.76 41.16 122.60 Non-Current Investments 4.54 3.38 1.15 Non-Current Liabili
Slide 35: Consolidated Cash Flow Statement
Consolidated Cash Flow Statement (In ₹ Cr) Particulars FY23 FY24 FY25 Cash Flow from Operating Activities 4.50 1.12 -29.05 Cash Flow from Investing Activities -6.49 -14.83 -35.75 Cash Flow from Financing Activities 2.46 15.57 67.11 Net Increase in Cash & Cash Equivalents 0.47 1.86 2.31 Investor Pres
Slide 36: Key Ratios
Key Ratios ROE ROCE (In %) EPS Book value (In ₹) 40.00% 92.00% 35.04% 35.00% 82.00% 29.34% 50.14 30.00% 72.00% 25.00% 62.00% 52.00% 47.60% 20.00% 42.00% 15.51% 27.08% 15.00% 20.58 32.00% 15.03 10.78 10.00% 22.00% 8.14 13.15% 1.68 5.00% 12.00% 2.00% 0.00% FY23 FY24 FY25 FY23 FY24 FY25 (In Times) (In
Slide 37: Stock Data
Stock Data As On 15-11-2025 As On 30-09-2025 NSE (SSEGL | INE0RFP01011) Share Holding Pattern Share Price (₹) 313.00 Market Capitalization (₹ Cr) 765.35 50.53% Promoter & Promoter Group No. of Shares Outstanding 2,44,52,064 Public Face Value (₹) 10.00 49.47% 355.00 – 140.00 52-week High-Low (₹) Shar
Slide 38: Investment Rationale
Investment Rationale Integrated Diagnostics Chain offering both pathology and radiology services under one roof, driving patient stickiness and cross-selling opportunities. Widespread Presence with operations across 35+ cities in 4 states, enabling deep regional penetration and first-mover advantage
Slide 39: Thank You
Thank You Chandan Healthcare Limited Biotech Park, Kursi Road, Lucknow 226021 U.P. Email: care@chandan.co.in Phone: 08069366666 Website: www.chandandiagnostic.com Kirin Advisors Private Limited 713-B, Lodha Supremus II, Wagle Estate, Thane West – 400 604 E-mail: info@kirinadvisors.com Phone: 022 410